First Trust BuyWrite Income ETF
Most Recent
Analyst Ratings and Recommendations for Sanofi
In 4Q17, Sanofi reported earnings per share of 1.06 euros on revenues of 8.7 billion euros.
Why Sanofi Has Received a Negative Outlook from Fitch Ratings
Fitch Ratings views Sanofi’s two recent acquisitions in close succession with a total value of 13.7 billion euros as a risk to its balance sheet.
Sanofi Leads the Hemophilia Space on Bioverativ Acquisition
According to Sanofi’s (SNY) 2020 roadmap, the company is focused on sustaining a position of leadership in some of its key markets, including the rare diseases space.
Understanding Sanofi’s 3Q17 Performance by Business Segment
Sanofi now reports its business in two segments: Human Pharmaceuticals and Sanofi Pasteur (or the Human Vaccines segment).
How Gilead’s Revenue Trended in 2016
Gilead Sciences (GILD) reported a decrease in revenues by ~7% to $30.4 billion during 2016 as compared to $32.6 billion during 2015.
